InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（2 笔）
内部人交易记录
首席财务官已披露买入
1
已披露卖出
2
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Shah Preetam, 首席财务官. Insider active across 2 companies, notably Cidara Therapeutics, Inc.. Cumulatively, 8 filings have been logged. Split: 1 buy · 2 sells. Total volume traded: €48k. History available since 12 November 2021. The latest transaction was disclosed on 2 February 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Shah Preetam
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
24,000 股0Common StockSEC:0001601485-26-000008:0
108,750 股0Common StockSEC:0001610618-24-000026:0
18,931 股@ US$0.669815.5% 占其流量Common StockSEC:0001610618-24-000009:0
90,000 股0Common StockSEC:0001610618-23-000028:0
6,648 股@ US$1.5312.7% 占其流量Common StockSEC:0001610618-23-000011:0
50,000 股0Common StockSEC:0001610618-22-000081:0
51,250 股0Common StockSEC:0001610618-22-000029:0
20,000 股@ US$1.5456.0% 占其流量Common StockSEC:0001610618-21-000106:0
标准退出：2022年2月10日 (T+90)
8 条申报中的 8 条
About Shah Preetam
Shah Preetam is Directeur Financier & Responsable Commercial at Cidara Therapeutics, Inc. (CFO & CBO) and is also listed at Elicio Therapeutics, Inc. (See Remarks). He has 8 filings in total, and across the sampled recent filings from 2021-11-15 to 2026-02-03, the amounts shown are EUR 26898 of buys and EUR 21108 of sells.
